Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Dec 22, 2009
Trial Information
Current as of June 25, 2025
Terminated
Keywords
ClinConnect Summary
Intestinal translocation of Gram-negative bacteria occurs in patients with advanced cirrhosis. Long-term oral administration of 400 mg/day of norfloxacin (a fluoroquinolone antibiotic) is known to induce selective intestinal decontamination against Gram-negative bacteria. A randomized, double-blind, placebo-controlled trial of oral norfloxacin (400 mg/day for 1 year) has been conducted in a small series of patients with advanced cirrhosis and low ascitic fluid protein concentrations \<1.5 g/dL. This trial showed that norfloxacin therapy significantly increased the 1-year probability of bein...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years,
- • Liver failure as defined by a Child-Pugh score ≥ 10 points,
- • Accept to participate,
- • Have health insurance.
- Exclusion Criteria:
- • Pregnancy,
- • Patient who has been treated with a quinolone in the month before his inclusion
- • Allergy to quinolones,
- • Hepatocellular carcinoma, and
- • HIV infection.
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clichy, , France
Patients applied
Trial Officials
MOREAU RICHARD
Principal Investigator
APHP
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials